Treatment time cut for microwave prostate therapy:
This article was originally published in Clinica
Urologix has begun a US clinical trial to assess the effect of reducing the treatment time of its non-surgical microwave heat ablation therapy for benign prostatic disease. Four patients have already been treated successfully with the Targis system after researchers more than halved the standard one-hour therapy, said the Minneapolis, Minnesota-based company. Positive results from the trial, which is being carried out under a supplemental investigational device exemption from the FDA, could lead to shorter treatment time without compromising patient comfort, complications or long-term clinical outcomes, according to Urologix.
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.